Dissecting monoclonal antibody mega-deals

mAbs

Volumn 1, Issue 2, 2009, Pages 172-178

  Villiger, Ralph ^a   Bogdan, Boris ^a  

^a Avance Basel GmbH   (Switzerland)

Author keywords

Deal structure; Licensing; Risk management; Strategy; Term sheet; Valuation

Indexed keywords

ELOTUZUMAB; MONOCLONAL ANTIBODY; OFATUMUMAB; UNCLASSIFIED DRUG;

BIOTECHNOLOGICAL PRODUCTION; DRUG COST; DRUG INDUSTRY; FINANCIAL MANAGEMENT; FUNDING; INVESTMENT; PROFIT; REVIEW;

ANTIBODIES, MONOCLONAL; BIOMEDICAL RESEARCH; BIOTECHNOLOGY; COOPERATIVE BEHAVIOR; DRUG INDUSTRY; HUMANS;

EID: 77953673558     PISSN: 19420862     EISSN: None     Source Type: Journal    
DOI: 10.4161/mabs.1.2.7638     Document Type: Review

References (7)

1. Bogdan B, Villiger R. Valuation in Life Sciences. A Practical Guide. Second Edition, Springer Verlag 2008; 171-173
2. DiMasi J, Grabowski H. The Cost of Biopharmaceutical R&D: Is Biotech Different? Manage Decis Econ 2007; 28:469-479
3. Reichert J. Success and failure: Clinical trials of protein therapeutics. Conference on plant-made pharmaceuticals 2005.
4. Reichert J, Rosensweig C, Faden L, Dewitz M. Monoclonal antibody successes in the clinic. Nat Biotechnol 2005; 23:1073-1078
5. Reichert J. Biopharmaceutical Approvals in the US Increase. RAJ Pharma 2004.
6. Schneider, Kalinke. Toward biosimilar monoclonal antibodies. Nat Biotechnol 2008; 26:985-990
7. Longman R. Why Investor's Don't Like Biotech Alliances. IN VIVO Blog March 2008.